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Abstract
Backround: Conjugated linoleic acids (CLA) are a group of positional and geometric isomers of linoleic acid with
proven beneficial influence on health. They show e.g. anticarcinogenic, antiobesity, and antiatherogenic effect. Milk,
dairy products and meat of poligastric animals are their most valuable dietary sources, with cis-9, trans-11 CLA (RA -
rumenic acid) being the predominant isomer. Dietary supplements with CLA became very popular, mainly among
the overweight and bodybuilders.
The aim of this study was to examine the influence of the food supplements with conjugated linoleic acid on car-
cinogenesis in female Sprague-Dawley rats and evaluation of CLA and other fatty acids distribution in their bodies.
Animals were divided into four groups depending on the diet supplementation (oil or Bio-C.L.A. (Pharma Nord
Denmark) given intragastrically) and presence or absence of carcinogenic agent (7,12-dimethylbenz[a]antharcene).
Animals were decapitated at 21st week of experiment and serum and microsomes were extracted.
Results and conclusions: The mammary tumours (adenocarcinoma) occurred in groups treated with DMBA. Diet
enriched with CLA decreased the cancer morbidity (67% in Bio-C.L.A. compared to 88% in oil) and delayed the
cancer induction (p = 0.0018). There were no differences in body and organs weight.
The supplement used in the study was a mixture of several fatty acids with the greatest proportion of CLA isomers:
trans-10, cis-12 (33%) and cis-9, trans-11 (31%). Both of them were present in tissues but the content of rumenic
acid was greater. Dietary supplementation had also significant impact on other fatty acids content, both in serum
and in microsomes.
Background
Conjugated Linoleic Acid (CLA) is a term for positional
and geometrical isomers of octadecadienoic acid with two
double bonds separated by only one single bond. They are
found in various types of food, mainly in milk and dairy
products and meat of ruminants. The predominant
CLA isomer in food is cis-9, trans-11-octadecadienoate
(Rumenic Acid - RA), which constitutes over 90% of all
CLA isomers [1]. Their content in food differs and
depends on many factors such as animal species, season,
way of feeding, place of pasture [2-6]. Commercially avail-
able supplements are the mixture of two main isomers:
cis-9, trans-11 CLA and trans-10, cis-12 CLA in equal pro-
portions. This group of fatty acids has been extensively
studied for recent years, in both in vivo and in vitro mod-
els, because of their beneficial biological effects: protection
against cancer [7-10], prevention of atherosclerosis
[11-14], reduction of obesity [15-17] and hypertension
[18]. However, despite numerous experiments their
mechanism of action is still under investigation.
As it is known that many cancers are associated with
diet, especially with dietary fat, we have focused on
changes in fatty acids profile as a possible effect of CLA
supplementation. The objectives of the present study
were: to monitor the influence of CLA supplementation
on mammary carcinogenesis in rats, to compare the
CLA distribution in tissues and to assess their influence
on other fatty acids profile.
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Animals
This research and guiding principles in the care of labora-
tory animals were approved by The Local Ethic Commis-
sion on Animal Experiments. Female Sprague-Dawley rats
(n = 33) were purchased at 30 day of age from Division of
Experimental Animals, Department of General and Experi-
mental Pathology (Medical University of Warsaw, Warsaw,
Poland).The animal room was kept at 21°C, in a 12 h light :
12 h dark cycle. A standard diet composed of 22.0% pro-
tein, 4.0% fat, 30.0% starch, 5.0% fibre, 6.5% minerals
(Labofeed H, Wytwórnia pasz “Morawski”, Żurawia 19,
Kcynia, Poland) was fed ad libitum. The daily food con-
sumption was about 10 g per rat. After 1-week adaptation
animals were randomly divided into four groups of 8 - 9
each. All rats from groups A1 and B1 received intragastri-
cally at 50 days of age a single dose of 80 mg/kg body
weight of carcinogenic agent - DMBA (7,12-Dimethylbenz
[a]anthracene, approx. 95%, Sigma-Aldrich) for the induc-
tion of mammary tumours. From that day all animals were
fed different dietary supplementation (oil - groups A1 and
G1, or Bio-C.L.A. (Pharma Nord Denmark) - groups B1
and D1, given intragastrically 0.15 cm
3/day) for the follow-
ing 15 weeks. During this period rats were palpated weekly
to detect the appearance of tumours. Table 1 shows the
characteristic of experimental groups. The fatty acids daily
intake is shown in Figure 1. The experiment was termi-
nated at the end of 21 week. All animals were decapitated
and exsanguinated.
Histopathological examination
The effectiveness of cancer induction in DMBA-treated
groups (A1 and B1) was determined as the percentage
of animals with tumours. Tumours were collected dur-
ing necropsy and some of them were fixed in 10% for-
malin. They were identified as adenocarcinomas and
papillary adenocarcinomas of mammary gland. In non-
DMBA-treated groups (D1 and G1) there were no spon-
taneous tumours.
Preparation of serum and microsomes
Serum was obtained by the centrifugation of blood for
10 min at 3000 rpm at 4°C and stored at -20°C in
Eppendorf test tubes until further analysis.
Hepatic microsomes were prepared according to mod-
ification of the Kłyszejko-Stefanowicz method [19].
A sample of liver (4 g) was mechanically homogenized
in saccharose solution (16 cm
3; 0.25 mol/dm3) buffered
with TRISS-buffer (pH 7.4). Homogenate was centri-
fuged for 10 min at 4000 rpm at 4°C. The sediment was
discarded and the supernatant fluid was centrifuged for
20 min at 16 000 × g at 4°C. The sediment was dis-
carded and the supernatant was centrifuged for 75 min
at 100 000 × g at 4°C. The supernatant was discarded
and the pellet was resuspended in 4 cm
3 0.25 mol/dm3
saccharose solution. The suspension of hepatic micro-
somes was stored in Eppendorf test tubes at -20°C until
further analysis.
Fatty acids analysis
Fatty acid analysis was made with GC with capillary col-
umn and flame-ionization detection.
The rat serums were thawed only once and samples of
100 μl were trans-esterificated according to the proce-
dure of Bondia-Pons et al. with slight modifications [20].
Without prior lipids extraction each sample was hydro-
lyzed by heating with 2.5 cm
3 sodium methylate reagent
(0.5 mol/dm
3) at 80°C and fatty acids were converted to
methyl esters by heating with 2.5 cm
3 of 14% boron tri-
fluoride-methanol reagent at 80°C for 3 min. FAME
were isolated with hexane (2 × 0.5 cm
3) after adding
1.0 cm3 of saturated sodium chloride solution. Organic
extracts were dried with anhydrous sodium sulphate and
evaporated to dryness under a stream of nitrogen.
FAME were diluted in 20 μl of hexane and stored at
-20°C. They were separated and quantified by GC using
Shimadzu GC-17A chromatograph equipped with flame
ionization detector. Injector was heated to 250°C and
detector was heated to 270°C. Separation was performed
on BPX 70 capillary column (60 m × 0.25 mm i.d., film
thickness: 0.20 μm, SGE) with helium as the carrier gas.
The initial oven temperature was 140°C for 1 min,
thereafter increased by 20°C/min to 200°C and held for
20 min and then increased by 5°C/min to 220°C and
held for 25 min. The whole analysis lasted 53 min.
FAME standards (Supelco 37 Component FAME Mix),
CLA FAME reference standard (Nu-Chek-Prep) and RA
FAME standard (methyl 9 cis 11 trans conjugated
Table 1 Characteristics of experimental groups
Group Number Supplementation Carcinogenic
agent
Morbidity Age of tumour appearance
(day of life) mean ± SD
Number of tumours per
individual mean ± SD
Tumour weight
(g) mean ± SD
A1 8 + oil + DMBA 88% 106 ± 14* 1,6 ± 1,1 3,76 ± 3,37
B1 9 + CLA + DMBA 67% 143 ± 19* 0,9 ± 0,8 2,69 ± 2,32
G1 8 + oil - -
D1 8 + CLA - -
(* significant differences between groups in Student’s t - test)
Białek et al. Lipids in Health and Disease 2010, 9:126
http://www.lipidworld.com/content/9/1/126
Page 2 of 9linoleate, Nu-Chek-Prep) were used to identify the fatty
acids present in samples.
The hepatic microsomes samples were thawed only
once and lipids were extracted according to Folch et al.
with slight modification [21]. 200 μlo fm i c r o s o m a ls u s -
pensions were mixed with 2.5 cm
3 chloroform : metha-
nol (2:1, v/v) and after vigorous shaking the chloroform
layer was separated. The residue was mixed with
1.5 cm
3 chloroform : methanol (2:1, v/v) and the extrac-
tion was repeated. Combined chloroform layers were
centrifuged for 10 min at 3000 rpm and the sediment
was discarded. The organic extract was evaporated to
dryness under a stream of nitrogen. The residue was
taken for the preparation of FAME according to proce-
dure previously described for serum.
The protein content of hepatic microsomes was mea-
sured by the method of Lowry et al. [22].
Statistical analysis
Results were evaluated with Statistica 9.0 (StatSoft,
Poland). The data were tested for normality with Shapiro -
Wilk test. The Student’s t-test and ANOVA were used to
test differences between groups for variables following
normality and Mann - Whitney U-test and Kruskal -
Wallis test was performed in case of the shortage of
normal distribution. P - value ≤ 0.05 was considered sig-
nificant. All data are mean values ± standard deviation.
Results and discussion
The percentage of tumour-bearing animals in each
DMBA-treated group is shown in Table 1. The higher
effectiveness of cancer induction was observed in A1
group supplemented with oil. 7 of 8 animals in this group
developed tumours, and 2 of them had 3 tumours, 2 had
2 tumours and 3 had 1 tumour. CLA supplementation
decreased the incidence of tumours (67% in B1 group in
comparison with 88% in A1 group). 6 of 9 rats supple-
mented with CLA developed tumours, and 2 animals had
2 tumours each. There were no significant differences in
the mean number of tumours per rat in DMBA-treated
groups although the percentage of animals with multiple
tumours was much higher in group supplemented with
oil than in CLA supplemented group (57% in A1 group
in comparison with 33% in B1 group). That confirms the
greater efficiency of DMBA-induced mammary carcino-
genesis in A1 group and suggests the greater invasiveness
of those tumours. There were no significant differences
in the mean weight of single tumour between DMBA-
treated groups but we observed the tendency to develop-
ing heavier tumours in A1 group supplemented with oil.
However 2 of 3 single tumours appeared to be much hea-
vier than the rest of tumours in A1 group (10.50 g and
11.93 g respectively) and the range of tumour weight was
wider in A1 group in comparison with B1 group. In B1
group there was only 1 single tumour much heavier than
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Figure 1 Fatty acids composition of experimental diets (% of total fatty acids).
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group A1 appeared on average 5 weeks earlier than in
group B1 (p = 0.0018). That indicates the ability of CLA
to inhibit the mammary adenocarcinoma development.
The lack of significant differences in the tumours weight
and in the number of tumours per rat between A1 and
B1 groups may be the result of the strength of action of
applied carcinogenic agent in the experimental condi-
tions. 7,12-Dimethylbenz[a]anthracene administered
intragastrically in a single dose of 80 mg/kg body weight
appeared to be so effective in the induction of mammary
tumours in both groups, that the preventive action of
Conjugated Linoleic Acid was not efficient enough and
confirmed with significant differences in all examined
parameters. Observed retardation and the tendency to
develop fewer and slighter tumours in CLA supplemen-
ted group clearly indicates the protective meaning of this
compounds in mammary carcinogenesis.
FAME profiles of serum and microsomes were mea-
sured using GC. In our experiment we analysed 21 fatty
acids. C20:4 n-6, C18:2 n-6, C16:0, C18:0 and C18:1 n-9
w e r ef o u n dt ob et h em a i nf a t t ya c i d si nt h es e r u mo f
all investigated groups (Table 2) whereas C18:0, C20:4
n-6, C16:0, C18:2 n-6 and C22:6 n-3 were the most
common in the hepatic microsomes (Table 3). Our
observations were similar to those of other authors.
Bondia-Pons et. al found C18:2 n-6, C16:0, C20:4 n-6,
C18:1 n-9 and C18:0 to be the most prominent in rats’
plasma [20]. The slight differences e.g. in share of AA
could have been caused by different fatty acids profiles
of applied diets. There were significant differences in
fatty acid concentration among examined groups. A1
showed the highest concentration of EPA in serum and
microsomes, significantly higher than other groups. Also
C 1 5 : 0a m o u n ti nm i c r o s o m e so fA 1w a sc o n s i d e r a b l y
greater. In contrast, the C12:0 content in serum samples
of this group was the lowest. We observed significantly
higher concentration of C12:0 and C17:1, and signifi-
cantly lower concentration of C18:3 n-3 and C22:6 n-3
in serum of G1. The highest C18:1 n-9 level was
observed in the samples of serum obtained from rats in
groups A1 and G1, whose diet contained noticeably
more of this fatty acid (Figure 1). Similar dependence
was evident for the C22:6 n-3 concentration. Jelińska et
al. found that higher concentration of C18:3 n-3 in
administered diet increased the EPA and DHA levels in
liver phospholipids of both non-DMBA- and DMBA-
treated rats [23]. Diet of B1 and D1 group, supplemen-
ted with Bio-C.L.A., was significantly richer in C18:3 n-3
which caused the increased content of this fatty acid’s
metabolite - C22:6 n-3 in serum of these groups. DHA
concentration in hepatic microsomes was also remark-
ably higher in CLA-treated groups. This observation is
in agreement with that of Eder et al. [24], who measured
Table 2 Fatty acids profile in serum of investigated dietary groups
A1 B1 G1 D1
Mean ± SD [%] p value < 0,05
C12:0 0,03 ± 0,01 0,04 ± 0,01 0,05 ± 0,01 0,04 ± 0,01 0,0234
C14:0 0,25 ± 0,04 0,24 ± 0,03 0,25 ± 0,05 0,25 ± 0,02
C15:0 0,36 ± 0,04 0,35 ± 0,06 0,27 ± 0,06 0,32 ± 0,05 0,0135
C16:0 17,87 ± 1,83 17,75 ± 1,36 16,21 ± 1,33 16,50 ± 1,11
C16:1 0,96 ± 0,57 0,52 ± 0,13 0,56 ± 0,18 0,50 ± 0,11
C17:0 0,51 ± 0,06 0,51 ± 0,08 0,53 ± 0,08 0,55 ± 0,05
C17:1 0,07 ± 0,03 0,06 ± 0,01 0,09 ± 0,01 0,08 ± 0,01 0,0121
C18:0 13,71 ± 1,61 14,38 ± 1,25 16,98 ± 0,67 15,98 ± 1,11 0,0000
C18:1 n-9 9,14 ± 1,38 7,65 ± 0,64 8,56 ± 0,89 7,19 ± 1,01 0,0075*
C18:2 n-6 21,16 ± 1,25 21,81 ± 0,72 18,49 ± 1,29 20,04 ± 1,03 0,0000
C18:3 n-6 0,36 ± 0,07 0,29 ± 0,05 0,39 ± 0,05 0,39 ± 0,06 0,0050
C18:3 n-3 2,52 ± 0,48 2,86 ± 0,37 2,14 ± 0,41 2,34 ± 0,39 0,0085
C20:0 0,10 ± 0,04 - 0,07 ± 0,01 0,06
cis-9, trans-11 CLA 0,05 ± 0,03 0,40 ± 0,12 - 0,34 ± 0,11 0,0037
trans-10, cis-12 CLA - 0,16 ± 0,08 - 0,10 ± 0,04
C20:3 n-6 0,66 ± 0,28 0,42 ± 0,06 0,36 ± 0,05 0,36 ± 0,05 0,0026*
C20:4 n-6 18,93 ± 3,88 20,05 ± 1,03 24,20 ± 2,01 23,44 ± 1,85 0,0004*
C20:3 n-3 0,21 ± 0,08 0,18 ± 0,10 0,21 ± 0,03 0,22 ± 0,10
C20:5 n-3 2,70 ± 0,40 2,08 ± 0,41 1,65 ± 0,32 2,01 ± 0,30 0,0000
C24:0 0,09 ± 0,03 0,09 ± 0,01 0,07 ± 0,02 0,06 ± 0,01 0,0315
C22:6 n-3 4,13 ± 0,50 4,44 ± 0,71 3,75 ± 0,37 4,45 ± 0,38 0,0315
(p value < 0,05 for those fatty acids with significant differences among groups in ANOVA or * Kruskal - Wallis test).
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in liver phosphatidylcholine of rats fed CLA-enriched
diet. Moreover, they detected in this group the increased
gene expression of Δ6-desaturase and increased conver-
sion of C18:3 n-3, but they linked that with the low con-
centration of C18:2 n-6 in that diet. However, in our
study the LA was the predominant fatty acid in B1 and
D1 group (Figure 1). That supports the hypothesis
about the dependence between CLA supplementation
and ALA metabolism. Senkal et al. observed that admin-
istration of long chain n-3 PUFA enriched diets lead to
increased incorporation of EPA and DHA both in serum
and tissues (liver, gut mucosa and tumour). They claim
that diet can modify not only lipid profile of different
tissues but also their immune response, especially
inflammatory response [25]. The data presented by Eder
et al. show that increased CLA intake and decreased n-6
fatty acids administration can lower the concentration
of several eicosanoids, which indicates that CLA can
also modulate the immune response [24]. However
Banni at al., who used in their experiment CLA-
enriched butter, observed the differences in the concen-
tration of C18:1, C18:2, C18:3 between the two dietary
groups, in both neutral lipids and phospholipids. Only
C20:4 content in some of the phospholipid fractions was
significantly lower in group with high CLA intake [26].
That disagrees with our results.
Moreover, not only diet but also carcinogenic agent
treatment had great influence on fatty acids profile, both
in serum and in microsomes of the investigated groups.
The lover levels of C17:1, C18:0, C18:2 n-6, C20:4 n-6
were observed in serum and microsomes of DMBA-trea-
ted groups, whereas C18:2 n-6 and C18:3 n-3 showed
the opposite tendency. Hoffmann et al. also observed
differences between fatty acids profile of healthy and
cancerous tissues, especially the n-3 and n-6 fatty acids
content [27,28].
Two main CLA isomers were detected in all samples
of serum and microsomes obtained from CLA supple-
mented groups and only in few samples from A1 group.
The CLA isomers were separated into two peaks, of
which the first one was identified as the cis-9, trans-11
CLA and the second one as the trans-10, cis-12 CLA.
Bio-C.L.A. used as the main source of CLA for B1 and
D1 group consisted of several fatty acids, with prevailing
share of two CLA isomers: cis-9, trans-11CLA: 33% and
cis-9, trans-11 CLA: 31%. However RA was shown to be
the prominent CLA isomer in each study group. Its
mean content in serum was 0.37 ± 0.11% of total fatty
acids whereas trans-10, cis-12 CLA constituted only
0.13 ± 0.07% of them. There were no significant differ-
ences in RA content in serum of B1 and D1 groups and
its concentration in A1 was significantly lower than in
CLA supplemented groups (Table 2). Zlatanos et al. in
Table 3 Fatty acids profile in hepatic microsomes of investigated dietary groups
A1 B1 G1 D1
Mean ± SD [%] p value < 0,05
C12:0 0,08 ± 0,05 0,05 ± 0,02 0,05 ± 0,02 0,07 ± 0,03
C14:0 0,29 ± 0,10 0,22 ± 0,05 0,22 ± 0,08 0,22 ± 0,06
C15:0 0,25 ± 0,04 0,22 ± 0,03 0,20 ± 0,06 0,20 ± 0,03 0,0065
C16:0 18,38 ± 1,54 18,63 ± 1,76 16,09 ± 1,31 16,62 ± 1,01 0,0019
C16:1 0,57 ± 0,32 0,32 ± 0,10 0,36 ± 0,19 0,23 ± 0,05 0,0140*
C17:0 0,64 ± 0,09 0,62 ± 0,09 0,64 ± 0,10 0,67 ± 0,06
C17:1 0,07 ± 0,02 0,07 ± 0,01 0,11 ± 0,02 0,10 ± 0,02 0,0001
C18:0 23,48 ± 3,13 23,33 ± 1,72 25,94 ± 1,95 27,32 ± 2,01 0,0023
C18:1 n-9 8,03 ± 3,88 5,80 ± 0,68 6,67 ± 1,47 4,59 ± 0,76 0,0009*
C18:2 n-6 14,37 ± 1,59 15,47 ± 1,11 13,84 ± 1,19 13,56 ± 1,61 0,0383
C18:3 n-6 0,18 ± 0,04 0,15 ± 0,04 0,21 ± 0,03 0,20 ± 0,04 0,0061
C18:3 n-3 1,53 ± 0,30 1,86 ± 0,32 1,39 ± 0,32 1,29 ± 0,39 0,0068
C20:0 0,08 ± 0,03 0,05 0,07 ± 0,06 0,09
cis-9, trans-11 CLA 0,09 ± 0,06 0,33 ± 0,09 - 0,25 ± 0,10 0,0128
trans-10, cis-12 CLA - 0,16 ± 0,08 - 0,08 ± 0,05
C20:3 n-6 0,69 ± 0,29 0,44 ± 0,07 0,40 ± 0,10 0,41 ± 0,07 0,0022*
C20:4 n-6 16,67 ± 2,79 17,28 ± 0,64 20,31 ± 1,79 19,82 ± 1,20 0,0003
C20:3 n-3 0,16 ± 0,05 0,14 ± 0,06 0,12 ± 0,02 0,11 ± 0,07
C20:5 n-3 1,29 ± 0,26 0,99 ± 0,23 0,84 ± 0,15 0,99 ± 0,12 0,0011
C24:0 0,10 ± 0,04 0,08 ± 0,02 0,06 ± 0,02 0,05 ± 0,01 0,0071*
C22:6 n-3 7,14 ± 0,92 8,36 ± 1,08 7,41 ± 0,99 8,30 ± 0,98 0,0375
(p value < 0,05 for those fatty acids with significant differences among groups in ANOVA or * Kruskal - Wallis test).
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ment with two major isomers: cis-9, trans-11 and trans-10,
cis-12 CLA (1:1), and also detected only RA in the amount
of 0.20 ± 0.02% whereas the other isomer was below the
detection limit [29]. Burdge et al. got similar results for
the plasma phosphatidylcholine, where cis-9, trans-11
CLA was the predominant isomer, even when the trans-
10, cis-12 CLA was the main ingredient of the admini-
strated dietary supplement [30]. The mean content of
RA in hepatic microsomes was 0.27 ± 0.11% of total fatty
acids, and the concentration of the second identified CLA
isomer was 0.12 ± 0.07%. We observed similar lack of
differences in RA amount in microsomes between B1 and
D1, and the significant lower content of this fatty acid in
A1 (Table 3) as in serum samples.
We compared the CLA isomers concentration in
serum and microsomes within A1 and B1 groups bet-
ween tumour-bearing and non-tumour-bearing animals
(Figure 2 and Figure 3). There were no significant differ-
ences either in cis-9, trans-11 CLA nor trans-10, cis-12
CLA content among the groups although the CLA
amount seemed to be slightly higher in serum of B1 rats
without tumours in comparison with B1 tumour-bearing
animals (0.45 ± 0.09% versus 0.38 ± 0.12% for cis-9,
trans-11 CLA, and 0.18 ± 0.07% versus 0.14 ± 0.08% for
trans-10, cis-12 CLA). Comparison of CLA isomers dis-
tribution in hepatic microsomes of B1 revealed the great
similarity to their distribution in serum (0.39 ± 0.02%
versus 0.31 ± 0.10% for cis-9, trans-11 CLA, and 0.20 ±
0.04% versus 0.14 ± 0.07% for trans-10, cis-12 CLA). This
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Figure 3 Content of trans-10, cis-12 CLA in serum and microsomes of individuals with or without tumours.
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mann et al., who found CLA content to be significantly
higher in total cancerous testicular tissue than in normal.
Only in mitochondrial fraction of cancerous tissue CLA
concentration tended to be lower than in normal tissue,
whereas other subcellular fractions showed the opposite
tendency [28].
Concentration of dominant RA in serum of rats fed
CLA diets were 9.25 ± 5.28 μg/cm3 (B1) and 6.27 ±
4.05 μg/cm3 (D1) respectively and they did not differ sig-
nificantly. Figure 4 shows the comparison of absolute RA
content in B1 serum between individuals with or without
developed tumours. The cis-9, trans-11 CLA content in
samples obtained from individuals without noticeable
tumours tended to be higher than in tumour-bearing
(10.51 ± 6.48 μg/cm3 versus 8.63 ± 5.13 μg/cm3),
although no significant differences were detected. The
total concentration of RA in hepatic microsomes suspen-
sion was calculated to the protein content. Its content in
CLA supplemented groups was similar (B1: 0.34 ± 0.18
μg/mg, and D1: 0.26 ± 0.29 μg/mg) and the distribution
pattern of this isomer in B1, depending on tumour devel-
opment, was very similar to its distribution in serum
(Figure 5). We observed a slight increase in RA content
in non-tumour-bearing individuals (0.47 ± 0.41 μg/mg
versus 0.28 ± 0.14 μg/mg).
Conclusions
Our findings confirm the great significance of Conju-
gated Linoleic Acid content in the diet on mammary
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Figure 4 Content of cis-9, trans-11 CLA in serum of B1 individuals with or without tumours.
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Figure 5 Content of cis-9, trans-11 CLA in microsomes of B1 individuals with or without tumours.
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Page 7 of 9carcinogenesis. CLA can inhibit the mammary tumours
development and also influence the other fatty acids
profile in tissues. Its content seemed to be slightly
higher in serum and microsomes of rats without
tumours in comparison with tumour-bearing animals.
They also show that both type and amount of fatty
acids in diet and environmental factors, such as carcino-
genic agents, influence the fatty acids profile. On the
other hand changes in fatty acids profile caused by CLA
supplementation can explain the numerous activities of
these fatty acids.
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